<DOC>
	<DOCNO>NCT01258322</DOCNO>
	<brief_summary>1 . Background : Cardiovascular disease ( CVD ) major cause mortality peritoneal dialysis ( PD ) patient , partly attributable high prevalence dysmetabolism . Currently , treatment available proven effect dyslipidemia , insulin resistance inflammation patient group . 2 . Study design : Randomized , cross-over trial . 3 . Settings Participants : Prevalent PD patient ( ＞20 year old , s-triglycerides ＞1.8 mmol/L ) never receive glitazones enrol . 4 . Interventions : Participants randomize receive either oral pioglitazone ( PIO ; 15 mg daily ) pioglitazone , 12 week random order , four-week wash . 5 . Outcomes measurement : The primary endpoint change serum triglyceride ( TG ) level PIO compare PIO . Secondary endpoint include change lipid level , HOMA-IR , adipocytokines CRP . Outcome effect assess use GLM .</brief_summary>
	<brief_title>Pioglitazone Attenuates Dysmetabolism Peritoneal Dialysis ( PD ) Patients</brief_title>
	<detailed_description>Cardiovascular disease ( CVD ) major cause mortality chronic kidney disease , include peritoneal dialysis ( PD ) patient . While survival show differ peritoneal hemodialysis , glucose uptake dialysate PD patient prone dyslipidemia , insulin resistance ( IR ) obesity . These metabolic disorder substantially link development CVD mortality patient population . Hypertriglyceridemia , report present 70 % PD patient , link glucose uptake peritoneum IRand promote vascular damage . Inflammation propose fundamental promoter atherosclerosis demonstrate dose-response relationship C-reactive protein ( CRP ) mortality . Adipocytokines , adiponectin，leptin resistin , also play important role development dyslipidemia , IR , atherosclerosis , inflammation CVD PD patient . Therefore , therapy target metabolic disorder important component treatment PD patient . Fibrates , peroxisome proliferator-activated receptor ( PPAR ) -α agonist , low serum TG , however , use PD patient limit limited efficacy often-appeared adverse effect rhabdomyolysis hepatic impairment . Nowadays , PPAR-γ agonist , thiazolidinediones ( TZDs ) , represent pioglitazone rosiglitazone , exert hypoglycemic property reduction insulin resistance . For ten year , use control blood glucose type 2 diabetes mellitus ( T2DM ) . In addition , TZDs also note beneficial effect lipid metabolism inflammation apart effect glycogenic control . However , study TZDs treatment metabolic disorder PD patient , especially nondiabetic subject scarce limit . We , therefore set investigate effect TZDs , pioglitazone hyperlipidemia , insulin resistance , inflammation adipokine dysmetabolism PD patient , especially nondiabetic patient .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>All patient receive one month regular continuous ambulatory peritoneal dialysis ( CAPD ) intermittent peritoneal dialysis ( IPD ) . The cause chronic renal failure diabetes nondiabetes . history allergy thiazolidinediones fenofibrate ; history sever adverse event fibrate ca n't tolerate patient ; patient followup regularly ; history myocardial infarction ( MI ) coronary artery bypass graft ( CABG ) surgery within past 1 month , history cerebral vascular accident ( CVA ) percutaneous transluminal coronary angioplasty ( PTCA ) within past 6 month ; chronic use nonsteroidal antiinflammatory drug ( NSAIDs ) , steroids immunosuppressive ; patient acute infection ; patient malignant tumor ; evidence severe hepatic injury ( ALT/AST＞100u/L ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2007</verification_date>
</DOC>